|
| [16] | V. Baier, O. Clayton, R. Nudischer, H. Cordes, A. R. P. Schneider, C. W. J. Thiel, T. Wittenberger, W. Moritz, L. M. Blank, U. P. Neumann, C. Trautwein, J. Kelm, Y. Schrooders, F. Caiment, H. Gmuender, A. Roth, J. V. Castell, J. Kleinjans, L. O. Küpfer,
"A Model-Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs", Clinical pharmacology & therapeutics, vol. 110, no. 5, 2021, pp. 1293–1301.
|
| [15] | J. Bednarsch, Z. Czigany, S. H. Loosen, L. Heij, L. Ruckgaber, H. Maes, J. Krause, M. Reen, B. Toteva, T. Vosdellen, P. Bruners, S. A. Lang, T. F. Ulmer, C. Roderburg, T. Lüdde, U. P. Neumann,
"Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection", Scientific reports, vol. 11, no. 1, 2021, pp. 17936.
|
| [14] | K. V. K. Koelfat, K. M. C. van Mierlo, T. M. Lodewick, J. G. Bloemen, G. van der Kroft, I. Amygdalos, U. P. Neumann, C. H. C. Dejong, P. L. M. Jansen, S. W. M. Olde Damink, F. G. Schaap,
"Bile Salt and FGF19 Signaling in the Early Phase of Human Liver Regeneration", Hepatology communications, vol. 5, no. 8, 2021, pp. 1400–1411.
|
| [13] | S. H. Loosen, C. Roderburg, P. H. Alizai, A. A. Roeth, S. M. Schmitz, M. Vucur, M. Luedde, D. Schöler, P. Paffenholz, F. Tacke, C. Trautwein, T. Lüdde, U. P. Neumann, T. F. Ulmer,
"Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases", Diagnostics, vol. 11, no. 11, 2021, pp. 1999.
|
| [12] | S. H. Loosen, V. van den Bosch, J. Gorgulho, M. Schulze-Hagen, J. Kandler, M. S. Jördens, F. Tacke, C. Loberg, G. Antoch, T. Brümmendorf, U. P. Neumann, C. K. Kuhl, T. Lüdde, C. Roderburg,
"Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy", Journal of Clinical Medicine, vol. 10, no. 7, 2021, pp. 1361.
|
| [11] | S. H. Loosen, H. H. Bock, M. Hellmich, W. T. Knoefel, C. Trautwein, V. Keitel, J. G. Bode, U. P. Neumann, T. Lüdde,
"Hospital Mortality and Current Trends in Liver Transplantation in Germany", Deutsches Ärzteblatt international, vol. 118, no. 29/30, 2021, pp. 497–502.
|
| [10] | C. Roderburg, S. H. Loosen, J. Bednarsch, P. H. Alizai, A. A. Roeth, S. M. Schmitz, M. Vucur, M. Luedde, P. Paffenholz, F. Tacke, C. Trautwein, T. F. Ulmer, U. P. Neumann, T. Lüdde,
"Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma", International journal of molecular sciences, vol. 22, no. 12, 2021, pp. 6569.
|
|
| [9] | J. Bednarsch, Z. Czigany, L. R. Heij, I. Amygdalos, D. Heise, P. Bruners, T. F. Ulmer, U. P. Neumann, S. A. Lang,
"The role of re-resection in recurrent hepatocellular carcinoma", Langenbeck's archives of surgery, vol. 407, no. 6, 2022, pp. 2381–2391.
|
| [8] | D. Liu, L. R. Heij, Z. Czigany, E. Dahl, S. A. Lang, T. F. Ulmer, T. Lüdde, U. P. Neumann, J. Bednarsch,
"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma", Journal of experimental & clinical cancer research, vol. 41, no. 1, 2022, pp. 127.
|
| [7] | D. Liu, L. Heij, Z. Czigany, E. Dahl, M. Den Dulk, S. Lang, T. F. Ulmer, U. P. Neumann, J. Bednarsch,
"The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma", Scientific reports, vol. 12, 2022, pp. 12691.
|
| [6] | S. H. Loosen, J. F. Halpaap, S. Labuhn, J. Bednarsch, P. H. Alizai, A. A. Roeth, S. A. Lang, M. Vucur, J. N. Kather, W. T. Knoefel, T. F. Ulmer, U. P. Neumann, C. Roderburg, T. Lüdde,
"Golgi Protein 73 (GP73) Serum Levels Predict Outcome after Resection of Biliary Tract Cancer", Cancers, vol. 14, no. 18, 2022, pp. 4428.
|
| [5] | S. H. Loosen, T. F. Ulmer, S. Labuhn, J. Bednarsch, S. Lang, P. H. Alizai, A. T. Schneider, M. Vucur, U. P. Neumann, T. Lüdde, C. Roderburg,
"Serum Levels of CXCL13 Are an Independent Predictor of Survival Following Resection of Biliary Tract Cancer", Cancers, vol. 14, no. 17, 2022, pp. 4073.
|
| [4] | G. Wang, L. R. Heij, D. Liu, E. Dahl, S. A. Lang, T. F. Ulmer, T. Lüdde, U. P. Neumann, J. Bednarsch,
"The Role of Single-Nucleotide Polymorphisms in Cholangiocarcinoma: A Systematic Review", Cancers, vol. 14, no. 23, 2022, pp. 5969.
|
|
| [3] | X. Chang, R. Korenblik, B. Olij, R. R. M. M. Knapen, C. van der Leij, D. Heise, M. den Dulk, U. P. Neumann, F. G. Schaap, R. M. van Dam, S. W. M. Olde Damink,
"Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant", Langenbeck's archives of surgery, vol. 408, no. 1, 2023, pp. 54.
|
| [2] | T. Essing, H. Bock, B. Wieland, G. Fluegen, J. Bednarsch, J. G. Bode, U. P. Neumann, C. Roderburg, S. H. Loosen, T. Lüdde,
"Clinical determinants of hospital mortality in liver failure", Zeitschrift für Gastroenterologie, vol. 61, no. 11, 2023, pp. 1472–1483.
|
| [1] | C. C. Otto, G. Wang, A. Mantas, D. Heise, P. Bruners, S. Lang, T. F. Ulmer, U. P. Neumann, L. R. Heij, J. Bednarsch,
"Time to surgery is not an oncological risk factor in HCC patients undergoing liver resection", Langenbeck's archives of surgery, vol. 408, no. 1, 2023, pp. 187.
|